Találati lista | Tudóstér

001-es BibID:	BIBFORM035329
Első szerző:	Bhattoa Harjit Pal (laboratóriumi szakorvos)
Cím:	Bone mineral density, biochemical markers of bone turnover, and hormonal status in men with systemic lupus erythematosus / Harjit Pal Bhattoa, Emese Kiss, Peter Bettembuk, Adam Balogh
Dátum:	2001
ISSN:	0172-8172
Megjegyzések:	The aim of this study was to evaluate bone mineral density (BMD), biochemical markers of bone turnover, and hormone levels in men with systemic lupus erythematosus (SLE). BMD at L2-L4 lumbar vertebrae (LS), left proximal femur neck, and radius at the ultradistal and mid-33% region was measured by dual-energy X-ray absorptiometry in 23 men with SLE (mean age, disease duration, and cumulative corticosteroid dose were 45.6 years, 11.9 years, and 33.410 g, respectively) and 40 healthy, age- and sex-matched controls. Biochemical markers of bone turnover, parathyroid hormone and 25-hydroxyvitamin D (25-OH-D), testosterone, and dehydroepiandrosterone sulfate (DHEAS) levels were measured. There was no difference in BMD between the SLE and control group. The prevalence of osteoporosis was 17.4% (4 out of 23), found at LS. Biochemical markers of bone turnover were within the reference range. There was a high prevalence of hypovitaminosis D (65.2%), hypotestosteronism (62.5%), and hypodehydroepiandrosterone sulfate (100%). There was no correlation between BMD and duration of disease, corticosteroid doses, SLE Disease Activity Index (SLEDAI), SLE Collaboration Clinics/American College of Rheumatology (SLICC/ARC) damage index, or markers of bone turnover. Bone-specific alkaline phosphatase (BSAP) (r, -0.500; P = 0.018) and DHEAS (r, -0.511; P = 0.013) correlated with daily corticosteroid dose. Despite corticosteroid therapy, bone mass in men with SLE was not decreased.
Tárgyszavak:	Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban egyetemen (Magyarországon) készült közlemény Biochemical markers of bone turnover Bone mineral density Corticosteroids Hormones Men Systemic lupus erythematosus 25 hydroxyvitamin D alkaline phosphatase biological marker corticosteroid prasterone sulfate testosterone adult aged article body mass bone density bone mineral bone turnover clinical article controlled study disease activity disease duration dual energy X ray absorptiometry femur neck human lumbar vertebra male osteoporosis priority journal systemic lupus erythematosus vitamin deficiency Aged Alkaline Phosphatase Bone Density Bone Remodeling Cross-Sectional Studies Female Glucocorticoids Humans Lupus Erythematosus, Systemic Male Middle Aged
Megjelenés:	Rheumatology International. - 21 : 3 (2001), p. 97-102. -
További szerzők:	Kiss Emese (1960-) (belgyógyász, immunológus) Bettembuk Péter Balogh Ádám (1940-) (szülész-nőgyógyász, endokrinológus szakorvos)
Internet cím:	Szerző által megadott URL Intézményi repozitóriumban (DEA) tárolt változat DOI
Borító:
Saját polcon:

001-es BibID:	BIBFORM017933
Első szerző:	Simon Zsófia (belgyógyász, haematológus)
Cím:	Successful rituximab-CHOP treatment of systemic lupus erythematosus associated with diffuse large B-cell non-Hodgkin lymphoma / Simon Zsófia, Tarr Tünde, Ress Zsuzsa, Gergely Lajos, Kiss Emese, Illés Árpád
Dátum:	2007
ISSN:	0172-8172
Megjegyzések:	The authors discuss the case of a 76-year-old female patient who has been suffering from subacute cutaneous lupus erythematosus since 1983. In 1999 she was diagnosed with systemic lupus erythematosus (SLE) based on her symptoms of malar rash, polyarthritis, leukopenia, autoimmune hemolytic anemia and positive anti-DNA antibody test. For this she received methylprednisolone and cyclophosphamide. After 3 years of remission, symptoms of cutaneous vasculitis appeared in 2004, which transitionally responded to treatment with azathioprin and methylprednisolone. Her cutaneous symptoms, however, progressed quickly along with generalized lymphadenopathy, splenomegaly and thrombocytopenia. Immunohistological evaluation of the lymph node biopsy showed diffuse large B-cell lymphoma. She developed complete remission after treatment with six-cycle R-CHOP (rituximab, and reduced doses of cyclophosphamide, vincristin, adriablastin, methylprednisolone). SLE became inactive and her symptoms of vasculitis resolved. The authors are bringing attention to one of the possible late complications of systemic lupus, and also underscoring that treatment with rituximab (+CHOP) was beneficial not only for the lymphoma but the SLE as well.
Tárgyszavak:	Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban egyetemen (Magyarországon) készült közlemény
Megjelenés:	Rheumatology International. - 28 : 2 (2007), p. 179-183. -
További szerzők:	Tarr Tünde (1976-) (belgyógyász, allergológus és klinikai immunológus) Ress Zsuzsa (1976-) (belgyógyász) Gergely Lajos (1965-) (belgyógyász, haematológus) Kiss Emese (1960-) (belgyógyász, immunológus) Illés Árpád (1959-) (belgyógyász, haematológus, onkológus)
Internet cím:	Intézményi repozitóriumban (DEA) tárolt változat DOI
Borító:
Saját polcon: